Identification of rare anti-phospholipid/protein co-factor autoantibodies in patients with systemic lupus erythematosus

Autoimmunity

Volumn 42, Issue 6, 2009, Pages 497-506

  Szodoray, Peter ^a   Tarr, Tunde ^a   Tumpek, Judit ^a   Kappelmayer, Janos ^a   Lakos, Gabriella ^b   Poor, Gyula ^c   Szegedi, Gyula ^a   Kiss, Emese ^c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF RHEUMATOLOGY AND PHYSIOTHERAPY   (Hungary)

Author keywords

Anti phospholipid syndrome; Clinical outcome; Disease outcome; Phospholipid co factor antibodies; SLE; Thrombotic events

Indexed keywords

ANNEXIN V ANTIBODY; ANTIPHOSPHOLIPID PROTEIN COFACTOR AUTOANTIBODY; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPOCORTIN 5; LUPUS ANTICOAGULANT; PHOSPHATIDYLSERINE; PHOSPHATIDYLSERINE ANTIBODY; PHOSPHOLIPID ANTIBODY; PROTHROMBIN; PROTHROMBIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD CLOTTING TEST; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RARE DISEASE; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ADULT; ANNEXIN A5; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; AUTOIMMUNE DISEASES; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PHOSPHATIDYLSERINES; PROTHROMBIN; THROMBOSIS;

EID: 70249093236     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930902882731     Document Type: Article

References (44)

1. Galli M, Comfurius P, Maassen C, Hemker HC, De Baets MH, Van Breda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335: 1544-1547.
2. Cheng HM, Chamley L. Cryptic natural autoantibodies and co-potentiators. Autoimmun Rev 2008;7:431-434.
3. Ambrozic A, Cucnik S, Tomsic N, Urbanija J, Lokar M, Babnik B, Rozman B, Iglic A, Kralj-Iglic V. Interaction of giant phospholipid vesicles containing cardiolipin and cholesterol with beta2-glycoprotein-I and anti-beta2-glycoprotein-I antibodies. Autoimmun Rev 2006;6:10-15.
4. Viard JP, Amoura Z, Bach JF. Association of anti-(2-glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992;93:181-186.
5. Cabral AR, Cabiedes J, Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-(2-glycoprotein-I than with antiphospholipid antibodies. J Rheum 1995;22:1988-1996.
6. Matsuda J, Saitoh N, Gotoh M, Gohchi K, Tsukamoto M. Prevalence of (2-glycoprotein I antibody in systemic lupus erythematosus patients with (2-glycoprotein I dependent antiphospholipid antibodies. Ann Rheum Dis 1995;54:73-75.
7. Bagnasco M, Grassia L, Pesce G. The management of the patient with unexpected autoantibody positivity. Autoimmun Rev 2007;6:347-353.
8. Lakos G, Kiss E, Regeczy N, Tarjan P, Soltesz P, Zeher M, Bodolay E, Szakony S, Sipka S, SzegediG. Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: Importance of IgA isotype. Clin Exp Immunol 1999;117:574-579.
9. Bertolaccini ML, Hughes GR. Antiphospholipid antibody testing: Which are most useful for diagnosis? Rheum Dis Clin North Am 2006;32:455-463.
10. Loeliger A. Prothrombin as a co-factor of the circulating anticoagulant in systemic lupus erythematosus? Thromb Diath Haemorrh 1959;3:237-256.
11. Bajaj S, Rapaport S, Fierer D, Herbst K, Schwartz D. A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 1983;61:684-692.
12. Kaburaki J, Kuwana M, Yamamoto M, Kawai S, Ikeda Y. Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus. Am J Hematol 1997;54: 209-213.
13. Nojima J, Kuratsune H, Suehisa E, Futsukaichi Y, Yamanishi H, Machii T, Iwatani Y, Kanakura Y. Association between the prevalence of antibodies to β2-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin Chem 2001;47: 1008-1015.
14. Bondanza A, Sabbadini MG, Pellegatta F, Zimmermann VS, Tincani A, Balestrieri G, Manfredi AA, Rovere P. Anti-β2 glycoprotein I antibodies prevent the de-activation of platelets and sustain their phagocytic clearance. J Autoimmun 2000;15: 469-477.
15. Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other 'antiphospholipid' antibodies. Blood 1994;84:2854-2867.
16. Chen Q, Stone PR, Woon ST, Ching LM, Hung S, McCowan LME, Chamley LW. Antiphospholipid antibodies bind to activated but not resting endothelial cells: Is an independent triggering event required to induce antiphospholipid antibody-mediated disease? J Thromb Res 2001; 114:101-111.
17. Del Papa N, Guidali L, Sala A, Buccellati C, Khamashta MA, Ichikawa K, Koike T, Balestrieri G, Tincani A, Hughes GR, Meroni PL. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arth Rheum 1997;40:551-561.
18. Ferro D, Pittoni V, Quintarelli C, Basili S, Saliola M, Caroselli C, Valesini G, Violi F. Coexistence of antiphospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with ongoing prothrombotic state. Circulation 1997;95:1425-1432.
19. Williams FM, Parmar K, Hughes GR, Hunt BJ. Systemic endothelial cell markers in primary antiphospholipid syndrome. Thromb Haemost 2000;84:742-746.
20. Becker BF, Heindl B, Kupatt C, Zahler S. Endothelial function and hemostasis. Z Kardiol 2000;89:160-167.
21. Galli M, Beretta G, Daldossi M, Bevers EM, Barbui T. Different anticoagulant and immunological properties of antiprothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost 1997;77:486-491.
22. Inanc M, Donohoe S, Ravirajan C, Radway-Bright E, Mackie I, Machin S, Isenberg D. Anti-β-2-glycoprotein I, anti prothrombin and anticardiolipin antibodies in a longitudinal study of patients with systemic lupus erythematosus and the antiphospholipid syndrome. Br J Rheumatol 1998;37: 1089-1094.
23. Pengo V, Biasiolo A, Brocco T, Tonetto S, Ruffatti A. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 1996;75:721-724.
24. Hochberg M. Updating American College of Rheumatology revised criteria for the classification of systemic lupus erhytematosus. Arth Rheum 1997;40:1725-1734.
25. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. J Am Coll Rheumatol 1999;42:1309.
26. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
27. Kiss E, Bhattoa HP, Bettembuk P, Balogh A, Szegedi G. Pregnancy in women with systemic lupus erythematosus. Eur J Obst Gynecol Reprod Biol 2002;101:129-134.
28. Arvieux J, Roussel B, Jacob MC, Colomb MG. Measurement of antiphospholipid antibodies by ELISA using b2-glycoprotein I as an antigen. J Immunol Methods 1991;143: 223-229.
29. Arvieux J, Darnige L, Caron C, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost 1995;74:1120-1125.
30. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgG are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991;66:629-632.
31. Roubey RAS. Immunology of the antiphospholipid antibody syndrome. Arth Rheum 1996;39:1444-1454.
32. Coulam CB, Kaider BD, Kaider AS, Janowicz P, Roussev RG. Antiphospholipid antibodies associated with implantation failure after IVF/ET. J Assist Reprod Genet 1997;14:603-608.
33. Satoh A, Suzuki K, Takayama E, Kojima K, Hidaka T, Kawakami M, Matsumoto I, Ohsuzu F. Detection of antiannexin IV and V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 1999;26:1715-1720.
34. Lopez LR, Dier KJ, Lopez D, Merrill JT, Fink CA. Anti-beta 2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol 2004;121:142-149.
35. Sorice M, Pittoni V, Circella A, Misasi R, Conti F, Longo A, Pontieri GM, Valesini G. Anti-prothrombin, but not pure anti cardiolipin antibodies are associated with the clinical features of the antiphospholipid antibody syndrome. Thromb Haemost 1998;80:713-715.
36. Gezer S. Antiphospholipid syndrome. Dis Mon 2003; 49: 696-741.
37. Amengual O, Atsumi T, Koike T. Specificities, properties, and clinical significance of antiprothrombin antibodies. Arth Rheum 2003;48:886-895.
38. Matsuda J, Saitoh N, Gohchi K, Gotoh M, Tsukamoto M. Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody. Am J Hematol 1994;47:56-58.
39. Lakos G, Kiss E, Regeczy N, Tarjan P, Soltesz P, Zeher M, Bodolay E, Szucs G, Szakony S, Sipka S, Szegedi G. Antiprothrombin and antiannexin V antibodies imply risk of thrombosis in patients with systemic autoimmune diseases. J Rheumatol 2000;27:924-929.
40. Nojima J, Kuratsune H, Suehisa E, Kitani T, Iwatani Y, Kanakura Y. Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies-co-existence of these antibodies enhances ADPinduced platelet activation in vitro. Thromb Haemost 2004; 91:967-976.
41. Soltesz P, Veres K, Lakos G, Kiss E, Muszbek L, Szegedi G. Evaluation of clinical and laboratory features of antiphospholipid syndrome: A retrospective study of 637 patients. Lupus 2003;12:302-307.
42. Meroni PL, Shoenfeld Y. Predictive, protective, orphan autoantibodies: The example of anti-phospholipid antibodies. Autoimmun Rev 2008;7:585-587.
43. Rao L, Hoang A, Rapaport S. Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid. Blood 1996;88:4173-4182.
44. Nojima J, Kuratsune H, Suehisa E, Futsukaichi Y, Yamanishi H, Machii T, Kitani T, Iwatani Y, Kanakura Y. Anti-prothrombin antibodies combined with lupus anticoagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus. Br J Haematol 2001;114:647-654.